Conference Day One
Wednesday April 24, 2024
8:00 am Morning Registration & Coffee
9:00 am Chair’s Opening Remarks
- Shelley Hartman Chief Executive Officer & Co-Founder, Aegle Therapeutics
Standardizing Practice for Clinical Use & Regulatory Progress
9:15 am Sources and Regulatory Takeaways From Products Marketed Around The Globe
- Duncan Ross Chief Executive Officer & Founder, Kimera Labs
Synopsis
- Exploring the popularity of the word exosome in regenerative medicine
- Addressing the diversity of sources of these cellular signaling machines
- Discussing sources as well as regulatory requirements in various markets
Advancing Isolation & Quantification of Exosomes to Ensure Accurate Analysis
9:45 am Characterization by Purification: Use of AEX, Density Gradient UC, & SEC to Analyze Charge, Density, & Size of Various Particle Subpopulations
- Kristin Luther Associate Director, Vesigen Therapeutics
Synopsis
- Building from the definitions of various subpopulations to detect clearly whether a sample is pure for the most accurate results
- Defining clear differentiating properties of these highlighted subpopulations for further use
- Creating clear strategies to transfer to future studies
10:15 am Morning Refreshments & Speed Networking
Synopsis
As some of the Exosome community is reunited, this session provides a valuable opportunity to make meaningful and lasting connections with your peers in the room. All attendees will have the opportunity to meet their fellow academic and industry experts.
11:45 am Generation of Stably Transduced MSCs to Purification of Engineered EVs
- Inkyu Lee Business Development Senior Manager , SHIFTBIO INC.
Synopsis
- Engineering MSCs through SBI’s Platform Technology, Extracellular Vesicle Sorting Motif (ESM)
- Exploring Upstream and Downstream Process Developments of Engineered EVs
- Ensuring Scalability and Batch-to-Batch Consistency of Engineered EVsÂ
12:15 pm Lunch & Networking
1:15 pm Case Study: Repair Assays & Large Scale Preparation & Validation of Reparative EVs
- Heather Branscome Researcher, PHD, George Mason University
Synopsis
- Reviewing a recent report from George Mason University and what it has uncovered for future use
- Building on pre-existing purification methods and what needs to be resolved
- Discussing the standards for large scale preparation for consistent future use
1:45 pm Case Study: Utilizing EV miRNAs to Uncover Underlying Molecular Mechanisms of Asthma Phenotypes
- Fahd Alhamdan Research Associate, Harvard Medical School
Synopsis
- Challenges in establishing a methodological workflow for EV miRNA-Sequencing analysis
- Bronchial Epithelial Cells secret EVs differ in size and miRNA cargo in apical and basal compartments
- EV plasma miR-17 and -106a clusters associated specifically with obesity-associated low type-2 asthma
2:15 pm Afternoon Refreshments
3:15 pm Methods of Quantification for Emerging Assays for Future Use
- Christopher Paradise Vice President - Research & Development, RION Therapeutics
Synopsis
- Validity of purification methods to ensure accuracy
- Using a combination of quantification techniques to differentiate exosome subtypes in heterogenous samples
- Ensuring more products are making it to later clinical stages of your pipeline
3:45 pm Roundtable Discussion: Future Directions & Predictions for Exosome Space with Regulatory Confidence
- Shelley Hartman Chief Executive Officer & Co-Founder, Aegle Therapeutics
Synopsis
- More practical and highly interactive breakout roundtables where attendees can crowdsource solutions and share opinions around pre-assigned topic areas. A valuable chance for attendees to unite around hot topics and debate best practice. This is a dedicated opportunity for you to voice your experience and identify unique solutions.
4:45 pm Chairs Closing Remarks
- Shelley Hartman Chief Executive Officer & Co-Founder, Aegle Therapeutics